FDA grants accelerated approval to epcoritamab-bysp for relapsed or refractory follicular lymphoma
- Kelly Wilson
- June 26, 2024
- Drugs
- No Comments
On June 26, 2024, the Food and Drug Administration granted accelerated approval to epcoritamab-bysp (Epkinly, Genmab US, Inc.), a bispecific CD20-directed CD3 T-cell engager, for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.